Navigation Links
Fuzionaire Diagnostics Announces Disease-Agnostic Platform to Radiolabel Any Molecule for Disease Diagnosis and Drug Discovery
Date:8/29/2018

Fuzionaire Diagnostics (“Fuzionaire Dx”), a radiopharmaceutical company unlocking the full power of positron emission tomography (PET), today launched its proprietary radiolabeling platform. Leveraging a fundamental breakthrough in alkali metal catalysis, Fuzionaire Dx is helping clinicians and researchers study and cure debilitating diseases, earlier, and with unprecedented precision. The platform is able to radiolabel any molecule at record-breaking speed, resulting in lower-cost, more targeted, and more effective radiopharmaceuticals.

Fuzionaire Dx’s patented method makes it possible to create fluorine-18 radiopharmaceuticals that contain a novel class of stabilized silicon-fluorine bond, a process that is much more efficient and uses existing radiochemistry infrastructure. These efficiency gains not only lower costs, they dramatically reduce the time it takes to prepare radiotracers. This is vital given the short (i.e., 109.8 min) half-life of the fluorine-18 radioisotope.

As a result, molecular imaging techniques like PET will be able to image a much broader range of biological targets and a greater breadth of diseases. This radiolabeling method also reduces the amount of off-target imaging and produces images with greater specificity and image clarity.

“Until now, no platform has existed to radiolabel any ligand with fluorine-18, and especially not with our speed,” said co-founder and CEO Nick Slavin. “We’ve developed a tool that will both enable the non-invasive diagnostic imaging market to enter a new era, and accelerate drug discovery programs to allow pharmaceutical companies to more effectively develop breakthrough therapies.”

The company is starting with diagnostics, where PET imaging is already used in the clinic for oncological, cardiovascular, and neurological applications to study, monitor, diagnose, and treat debilitating diseases.

PET imaging is also valuable from the earliest stages of drug discovery, providing unique pharmacokinetic information for new drug candidates and quantification of drug properties in vivo. Fuzionaire Dx’s radiolabeling platform can make PET a ubiquitous, essential, and cost-effective tool that improves decision-making and increases returns on R&D investment throughout virtually all stages of the drug development process.

Several leading clinical research centers and foundations are leveraging Fuzionaire Dx’s radiolabeling platform to study and treat traditionally challenging diseases in areas such as neurology and oncology.

”As we enter the world of precision medicine, Fuzionaire Dx provides technology that could help track and image cancers in an unprecedented way, which will ultimately allow for many novel approaches in cancer therapeutics,” said Douglas Scherr, MD, Professor of Oncology and Clinical Director of Urologic Oncology at Weill Medical College of Cornell University.

Fuzionaire Dx’s technology is based on a breakthrough discovery by Anton Toutov during his PhD studies under Nobel Laureate Robert Grubbs at Caltech creating a new branch of catalysis based on Earth-abundant alkali metals like potassium and sodium.

Until now, producing a catalytic reaction has generally required either the use of rare, expensive metals or high temperature and pressures.

This discovery makes it possible to initiate chemical processes at ambient temperatures and pressures without using precious metals, lowering cost, improving efficiency, and unlocking previously unthinkable chemical reactions.

“Our mission is to apply our core technology to build solutions that can tangibly improve the human condition,” said co-founder and CSO Anton Toutov. “We have the same primary goal of any healthcare worker, which is to save and improve lives. By improving the underlying chemistry of existing processes and inventing new ones, we are unlocking untapped potential to do just that.”

Fuzionaire Dx is led by co-founders Nick Slavin (CEO), Anton Toutov, PhD (CSO), and Nova Spivack. The company is also supported by a team of world-class advisors, including Michael Phelps, the inventor of PET, Jason Lewis, former president of the World Molecular Imaging Society, and Kristin Swanson, a mathematical oncologist at the Mayo Clinic whose research interests include clinical trial design and mathematical modeling for the treatment of patients with brain cancer.

To learn more, please visit: http://www.fuzionairedx.com

About Fuzionaire Diagnostics:

Fuzionaire Diagnostics (“Fuzionaire Dx”) is a radiopharmaceutical company. Our radiolabeling platform unlocks the power of PET to help detect and treat any disease.

The barriers to better imaging are the result of basic limitations in chemistry. Leveraging a breakthrough in alkali metal catalysis, Fuzionaire Dx is radically improving the resolution, safety, use, and cost of PET imaging.

Our patented HetSiFA™ compositions, which are synthesized using our alkali metal catalysts, can bioconjugate to any disease-targeting ligand, often at record-breaking speed.

For the first time, it is now possible to rapidly produce a broad range of fluorine-18 radiopharmaceuticals based on a single disease-agnostic platform. Using our technology, researchers and clinicians can detect, localize, diagnose, and monitor more diseases, earlier, and with unprecedented precision. Pharmaceutical companies can improve their drug discovery process along virtually every phase of development.

Fuzionaire Dx was co-founded by a team including CEO Nick Slavin, Chief Science Officer Anton Toutov, PhD, and Nova Spivack, and is advised by Michael E. Phelps, the inventor of PET.

We are unlocking the true power of PET. If you’re interested in learning more, visit us at: http://www.fuzionairedx.com.

Read the full story at https://www.prweb.com/releases/fuzionaire_diagnostics_announces_disease_agnostic_platform_to_radiolabel_any_molecule_for_disease_diagnosis_and_drug_discovery/prweb15720578.htm.


'/>"/>
Source: PRWeb
Copyright©2018 Vocus, Inc.
All rights reserved


Related biology news :

1. DNAnexus and QIAGEN Team Up in Education Webinar: Scaling End-to-End NGS Solutions for Clinical Diagnostics in the Cloud
2. Plum Alley Closes $1.5M in Syndicate with Women and Men Investing in CRISPR-based Diagnostics Company
3. Nanomedical Diagnostics Agile R100 Graphene Biosensor Characterizes Difficult-to-Study MYC Oncoprotein for Cancer Research
4. Heart Health Innovator Boston Heart Diagnostics Joins American College of Lifestyle Medicine Corporate Roundtable
5. Singulex and Thermo Fisher Scientific Enter into License and Supply Agreement to bring Next Generation Immunodiagnostics to Sepsis and SIRS Diagnostics
6. Force Diagnostics and higi Partner to Provide Innovative Services to Life Insurance Industry:
7. Molecular Diagnostics - Global Market Size, Strategy and Forecasts - 2015 to 2019
8. handyem and FlowMetric Diagnostics announce their partnership in the development of Flow Cytometry- Based Solutions in diagnostic capabilities
9. MicroRNA: An Insight to miRNA-based microarrays, diagnostics and therapeutics Overview, Cambridge Healthtech Advisors
10. Kalorama Report: Sizable Number of Acquisitions and Joint Ventures in Molecular Diagnostics
11. OncoPlex Diagnostics Announces the Addition of the Androgen Receptor Protein to Their Quantitative Breast Cancer Proteomic Panel
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/14/2019)... ... , ... Gateway Genomics , a leading developer of direct-to-consumer genetic tests ... annual Inc. 500|5000 list of fastest growing private companies, in the first year ... and generating revenue by March 31, 2015. Ranking in the list is determined by ...
(Date:8/14/2019)... Calif. (PRWEB) , ... August 13, 2019 , ... Dr. Julie Reck of Veterinary ... to her patients. Her first stem cell patient, her own geriatric Australian Shepherd, ... According to Dr. Reck, Simon wanted to play but his body was weak, and he ...
(Date:8/6/2019)... , ... August 06, 2019 , ... ... a computational modeling system that could have far-reaching implications for personalized medicine, especially ... squares regression (PLSR), is able to predict which stem cell donors and manipulation ...
Breaking Biology News(10 mins):
(Date:9/11/2019)... ... September 09, 2019 , ... ... trial randomization and drug supply chain management, today announced its new technology partnership ... sciences industry. , “The integration between Veeva Vault EDC and our IRT will ...
(Date:9/9/2019)... ... 09, 2019 , ... Visikol CEO Dr. Michael Johnson recently gave a ... to characterize 3D cell culture models. The inherent problem of characterizing 3D cell culture ... to image through and therefore traditional wide-field or even confocal microscopy only tells you ...
(Date:9/4/2019)... (PRWEB) , ... September 03, ... ... provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, ... Director, Science & Technology will present at the upcoming Nordic Life Science ...
(Date:8/29/2019)... Kan. (PRWEB) , ... August 28, 2019 , ... ... expertise and wide-ranging DuPont™ Danisco® ingredient solutions to attendees at the International Baking ... to solve today’s baking challenges from optimizing production efficiency to cost and waste ...
Breaking Biology Technology: